Your browser doesn't support javascript.
loading
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
Okumura, Satoshi; Ishihara, Mikiya; Kiyota, Naomi; Yakushijin, Kimikazu; Takada, Kohichi; Kobayashi, Shinichiro; Ikeda, Hiroaki; Endo, Makoto; Kato, Koji; Kitano, Shigehisa; Matsumine, Akihiko; Nagata, Yasuhiro; Kageyama, Shinichi; Shiraishi, Taizo; Yamada, Tomomi; Horibe, Keizo; Takesako, Kazuto; Miwa, Hiroshi; Watanabe, Takashi; Miyahara, Yoshihiro; Shiku, Hiroshi.
Affiliation
  • Okumura S; Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Ishihara M; Cancer Center, Mie University Hospital, Tsu, Mie, Japan mishihara@med.mie-u.ac.jp miyahr-y@med.mie-u.ac.jp.
  • Kiyota N; Cancer Center, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Yakushijin K; Department of Medical Oncology and Haematology, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Takada K; Department of Medical Oncology and Haematology, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Kobayashi S; Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan.
  • Ikeda H; Department of Surgery, Nagasaki University Hospital, Nagasaki, Japan.
  • Endo M; Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Kato K; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Kitano S; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Matsumine A; Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Nagata Y; Department of Orthopaedics and Rehabilitation Medicine, Unit of Surgery, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
  • Kageyama S; Department of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Shiraishi T; Department of Medical Oncology/Chemotherapy Center, Suzuka Kaisei Hospital, Suzuka, Mie, Japan.
  • Yamada T; Department of Pathology, Kuwana City Medical Center, Kuwana, Mie, Japan.
  • Horibe K; Department of Medical Innovation, Osaka University Hospital, Osaka, Japan.
  • Takesako K; Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Miwa H; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
  • Watanabe T; Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Miyahara Y; Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Shiku H; Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
BMJ Open ; 12(11): e065109, 2022 Nov 14.
Article in En | MEDLINE | ID: mdl-36375974
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Chimeric Antigen / Neoplasms Type of study: Clinical_trials / Guideline Aspects: Ethics Limits: Humans Language: En Journal: BMJ Open Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Chimeric Antigen / Neoplasms Type of study: Clinical_trials / Guideline Aspects: Ethics Limits: Humans Language: En Journal: BMJ Open Year: 2022 Document type: Article